Research
Hormonal
In cancer survivors with obesity, metformin treatment resulted in a significant decrease in IGF-1 levels by 7.2 ng/mL at 6 months.
Metformin may be considered as a treatment option for reducing IGF-1 levels in obese cancer survivors.
StrongSupportsmedium confidence
The significant decrease of IGF-1 remained in participants with obesity at 6 months (mean difference in change: -7.2 ng/mL; 95% CI: -13.3 to -1.1).
Why this rating
Based on the randomized controlled trial design.
Source
Effects of Behavioral Weight Loss and Metformin on IGFs in Cancer Survivors: A Randomized Trial
Hsin‐Chieh Yeh et al. · The Journal of Clinical Endocrinology & Metabolism · 2021
rct · n=121Cited 22×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →